June 17, 2013
Boehringer Ingelheim (BI) Japan announced on June 14 that the efficacy of its anticoagulant dabigatran etexilate (brand name in Japan: Prazaxa), a direct thrombin inhibitor, has been confirmed for the prevention of strokes in atrial fibrillation (AF) patients in Asian...read more